Innovating Works

FLUIDITY

Financiado
Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments
Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeti... Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses. By acting on cell membrane’s fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks. Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions. We will perform an accelerated development process as our molecule has already proved it safety in humans. COVID-19 will be the first demonstrator of our molecule’s efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses. ver más
31/12/2024
5M€
Duración del proyecto: 24 meses Fecha Inicio: 2022-12-20
Fecha Fin: 2024-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-20
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 5M€
Líder del proyecto
MELETIOS THERAPEUTICS No se ha especificado una descripción o un objeto social para esta compañía.